Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer

F. Roy MacKintosh, Preston C. Sprenkle, Louise C. Walter, Lori Rawson, Robert Jeffrey Karnes, Christopher H. Morrell, Michael W. Kattan, Cayce B. Nawaf, Thomas B. Neville

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility. We evaluated prostate cancer death in relation to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans Affairs database, we identified 230,081 men aged 50-89 years diagnosed with prostate cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific death over time was calculated for patients stratified by age group (e.g., 50-59 years, through 80-89 years) and PSA range at diagnosis (10 ranges) using Kaplan-Meier methods. Risk of 10-year prostate cancer mortality across age and PSA was compared using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5% of men diagnosed with prostate cancer died of cancer during the 10-year study period (mean follow-up = 3.7 years). Higher PSA values prior to diagnosis predict a higher risk of death in all age groups (p < 0.0001). Within the same PSA range, older age groups are at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7-10 ng/mL, cancer-specific death, 10 years after diagnosis, increased from 7% for age 50-59 years to 51% for age 80-89 years. Men older than 70 years are more likely to die of prostate cancer at any PSA level than younger men, suggesting prostate cancer remains a significant problem among older men (even those aged 80+) and deserves additional study.

Original languageEnglish (US)
Article number157
JournalFrontiers in Oncology
Volume6
Issue numberJUN
DOIs
StatePublished - Jun 28 2016

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Age Groups
Veterans
Neoplasms
Databases
Mortality

Keywords

  • Death risk
  • Life expectancy
  • Older men
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MacKintosh, F. R., Sprenkle, P. C., Walter, L. C., Rawson, L., Karnes, R. J., Morrell, C. H., ... Neville, T. B. (2016). Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer. Frontiers in Oncology, 6(JUN), [157]. https://doi.org/10.3389/fonc.2016.00157

Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer. / MacKintosh, F. Roy; Sprenkle, Preston C.; Walter, Louise C.; Rawson, Lori; Karnes, Robert Jeffrey; Morrell, Christopher H.; Kattan, Michael W.; Nawaf, Cayce B.; Neville, Thomas B.

In: Frontiers in Oncology, Vol. 6, No. JUN, 157, 28.06.2016.

Research output: Contribution to journalArticle

MacKintosh, FR, Sprenkle, PC, Walter, LC, Rawson, L, Karnes, RJ, Morrell, CH, Kattan, MW, Nawaf, CB & Neville, TB 2016, 'Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer', Frontiers in Oncology, vol. 6, no. JUN, 157. https://doi.org/10.3389/fonc.2016.00157
MacKintosh, F. Roy ; Sprenkle, Preston C. ; Walter, Louise C. ; Rawson, Lori ; Karnes, Robert Jeffrey ; Morrell, Christopher H. ; Kattan, Michael W. ; Nawaf, Cayce B. ; Neville, Thomas B. / Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer. In: Frontiers in Oncology. 2016 ; Vol. 6, No. JUN.
@article{c55e0a87e2854afc9153b190303d0b23,
title = "Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer",
abstract = "A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility. We evaluated prostate cancer death in relation to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans Affairs database, we identified 230,081 men aged 50-89 years diagnosed with prostate cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific death over time was calculated for patients stratified by age group (e.g., 50-59 years, through 80-89 years) and PSA range at diagnosis (10 ranges) using Kaplan-Meier methods. Risk of 10-year prostate cancer mortality across age and PSA was compared using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5{\%} of men diagnosed with prostate cancer died of cancer during the 10-year study period (mean follow-up = 3.7 years). Higher PSA values prior to diagnosis predict a higher risk of death in all age groups (p < 0.0001). Within the same PSA range, older age groups are at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7-10 ng/mL, cancer-specific death, 10 years after diagnosis, increased from 7{\%} for age 50-59 years to 51{\%} for age 80-89 years. Men older than 70 years are more likely to die of prostate cancer at any PSA level than younger men, suggesting prostate cancer remains a significant problem among older men (even those aged 80+) and deserves additional study.",
keywords = "Death risk, Life expectancy, Older men, Prostate cancer, Prostate-specific antigen",
author = "MacKintosh, {F. Roy} and Sprenkle, {Preston C.} and Walter, {Louise C.} and Lori Rawson and Karnes, {Robert Jeffrey} and Morrell, {Christopher H.} and Kattan, {Michael W.} and Nawaf, {Cayce B.} and Neville, {Thomas B.}",
year = "2016",
month = "6",
day = "28",
doi = "10.3389/fonc.2016.00157",
language = "English (US)",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer

AU - MacKintosh, F. Roy

AU - Sprenkle, Preston C.

AU - Walter, Louise C.

AU - Rawson, Lori

AU - Karnes, Robert Jeffrey

AU - Morrell, Christopher H.

AU - Kattan, Michael W.

AU - Nawaf, Cayce B.

AU - Neville, Thomas B.

PY - 2016/6/28

Y1 - 2016/6/28

N2 - A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility. We evaluated prostate cancer death in relation to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans Affairs database, we identified 230,081 men aged 50-89 years diagnosed with prostate cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific death over time was calculated for patients stratified by age group (e.g., 50-59 years, through 80-89 years) and PSA range at diagnosis (10 ranges) using Kaplan-Meier methods. Risk of 10-year prostate cancer mortality across age and PSA was compared using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5% of men diagnosed with prostate cancer died of cancer during the 10-year study period (mean follow-up = 3.7 years). Higher PSA values prior to diagnosis predict a higher risk of death in all age groups (p < 0.0001). Within the same PSA range, older age groups are at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7-10 ng/mL, cancer-specific death, 10 years after diagnosis, increased from 7% for age 50-59 years to 51% for age 80-89 years. Men older than 70 years are more likely to die of prostate cancer at any PSA level than younger men, suggesting prostate cancer remains a significant problem among older men (even those aged 80+) and deserves additional study.

AB - A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility. We evaluated prostate cancer death in relation to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans Affairs database, we identified 230,081 men aged 50-89 years diagnosed with prostate cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific death over time was calculated for patients stratified by age group (e.g., 50-59 years, through 80-89 years) and PSA range at diagnosis (10 ranges) using Kaplan-Meier methods. Risk of 10-year prostate cancer mortality across age and PSA was compared using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5% of men diagnosed with prostate cancer died of cancer during the 10-year study period (mean follow-up = 3.7 years). Higher PSA values prior to diagnosis predict a higher risk of death in all age groups (p < 0.0001). Within the same PSA range, older age groups are at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7-10 ng/mL, cancer-specific death, 10 years after diagnosis, increased from 7% for age 50-59 years to 51% for age 80-89 years. Men older than 70 years are more likely to die of prostate cancer at any PSA level than younger men, suggesting prostate cancer remains a significant problem among older men (even those aged 80+) and deserves additional study.

KW - Death risk

KW - Life expectancy

KW - Older men

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84982826643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982826643&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00157

DO - 10.3389/fonc.2016.00157

M3 - Article

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 157

ER -